1. Home
  2. CDLR vs ANIP Comparison

CDLR vs ANIP Comparison

Compare CDLR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

HOLD

Current Price

$25.84

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$78.59

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLR
ANIP
Founded
2008
2001
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2023
1999

Fundamental Metrics

Financial Performance
Metric
CDLR
ANIP
Price
$25.84
$78.59
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
91.3K
314.5K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
419.23
EPS
N/A
3.32
Revenue
N/A
$206,547,000.00
Revenue This Year
$51.71
$21.01
Revenue Next Year
$34.41
$17.59
P/E Ratio
$7.39
$23.63
Revenue Growth
N/A
2.47
52 Week Low
$15.37
$56.71
52 Week High
$26.79
$99.50

Technical Indicators

Market Signals
Indicator
CDLR
ANIP
Relative Strength Index (RSI) 61.53 55.79
Support Level $19.57 $75.20
Resistance Level $26.79 $85.12
Average True Range (ATR) 0.67 2.63
MACD 0.33 0.73
Stochastic Oscillator 91.78 60.60

Price Performance

Historical Comparison
CDLR
ANIP

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: